Topical Fluoroquinolone Use as a Risk Factor for In Vitro Fluoroquinolone Resistance in Ocular Cultures | Allergy and Clinical Immunology | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
1.
Constantinou  MDaniell  MSnibson  GRVu  HTTaylor  HR Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.  Ophthalmology 2007;114 (9) 1622- 1629PubMedGoogle ScholarCrossref
2.
Gangopadhyay  NDaniell  MWeih  LTaylor  HR Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers.  Br J Ophthalmol 2000;84 (4) 378- 384PubMedGoogle ScholarCrossref
3.
Khokhar  SSindhu  NMirdha  BR Comparison of topical 0.3% ofloxacin to fortified tobramycin-cefazolin in the therapy of bacterial keratitis.  Infection 2000;28 (3) 149- 152PubMedGoogle ScholarCrossref
4.
Chang  DFBraga-Mele  RMamalis  N  et al. ASCRS Cataract Clinical Committee, Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey.  J Cataract Refract Surg 2007;33 (10) 1801- 1805PubMedGoogle ScholarCrossref
5.
Brueggemann  AB Antibiotic resistance mechanisms among pediatric respiratory and enteric pathogens: a current update.  Pediatr Infect Dis J 2006;25 (10) 969- 973PubMedGoogle ScholarCrossref
6.
Hammerum  AMHeuer  OEEmborg  HD  et al.  Danish integrated antimicrobial resistance monitoring and research program.  Emerg Infect Dis 2007;13 (11) 1632- 1639PubMedGoogle ScholarCrossref
7.
Rangaraj  GGranwehr  BPJiang  YHachem  RRaad  I Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.  Cancer 2010;116 (4) 967- 973PubMedGoogle ScholarCrossref
8.
Gaynor  BDChidambaram  JDCevallos  V  et al.  Topical ocular antibiotics induce bacterial resistance at extraocular sites.  Br J Ophthalmol 2005;89 (9) 1097- 1099PubMedGoogle ScholarCrossref
9.
Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement: CLSI document M100-S19. Accessed February 15, 2011
10.
Arason  VASigurdsson  JAErlendsdottir  HGudmundsson  SKristinsson  KG The role of antimicrobial use in the epidemiology of resistant pneumococci: a 10-year follow up.  Microb Drug Resist 2006;12 (3) 169- 176PubMedGoogle ScholarCrossref
11.
Baquero  FBaquero-Artigao  GCantón  RGarcía-Rey  C Antibiotic consumption and resistance selection in Streptococcus pneumoniae.  J Antimicrob Chemother 2002;50 ((Suppl S2)) 27- 37PubMedGoogle ScholarCrossref
12.
Barkai  GGreenberg  DGivon-Lavi  NDreifuss  EVardy  DDagan  R Community prescribing and resistant Streptococcus pneumoniae.  Emerg Infect Dis 2005;11 (6) 829- 837PubMedGoogle ScholarCrossref
13.
Lipsitch  MSamore  MH Antimicrobial use and antimicrobial resistance: a population perspective.  Emerg Infect Dis 2002;8 (4) 347- 354PubMedGoogle ScholarCrossref
14.
Rosenblatt-Farrell  N The landscape of antibiotic resistance.  Environ Health Perspect 2009;117 (6) A244- A250PubMedGoogle ScholarCrossref
15.
Seppälä  HKlaukka  TVuopio-Varkila  J  et al. Finnish Study Group for Antimicrobial Resistance, The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland.  N Engl J Med 1997;337 (7) 441- 446PubMedGoogle ScholarCrossref
16.
van de Sande-Bruinsma  NGrundmann  HVerloo  D  et al. European Antimicrobial Resistance Surveillance System Group; European Surveillance of Antimicrobial Consumption Project Group, Antimicrobial drug use and resistance in Europe.  Emerg Infect Dis 2008;14 (11) 1722- 1730PubMedGoogle ScholarCrossref
17.
Rogues  AMDumartin  CAmadéo  B  et al.  Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals.  Infect Control Hosp Epidemiol 2007;28 (12) 1389- 1395PubMedGoogle ScholarCrossref
18.
Cheng  VCLi  IWWu  AK  et al.  Effect of antibiotics on the bacterial load of methicillin-resistant Staphylococcus aureus colonisation in anterior nares.  J Hosp Infect 2008;70 (1) 27- 34PubMedGoogle ScholarCrossref
19.
Hwang  DG Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.  Surv Ophthalmol 2004;49 ((Suppl 2)) S79- S83PubMedGoogle ScholarCrossref
20.
Chacko  JKuruvila  MBhat  GK Factors affecting the nasal carriage of methicillin-resistant Staphylococcus aureus in human immunodeficiency virus-infected patients.  Indian J Med Microbiol 2009;27 (2) 146- 148PubMedGoogle ScholarCrossref
21.
Lautenbach  EFishman  NOBilker  WB  et al.  Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections.  Arch Intern Med 2002;162 (21) 2469- 2477PubMedGoogle ScholarCrossref
22.
Harbarth  SHuttner  BGervaz  P  et al.  Risk factors for methicillin-resistant Staphylococcus aureus surgical site infection.  Infect Control Hosp Epidemiol 2008;29 (9) 890- 893PubMedGoogle ScholarCrossref
23.
Asbell  PASahm  DFShaw  MDraghi  DCBrown  NP Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005.  J Cataract Refract Surg 2008;34 (5) 814- 818PubMedGoogle ScholarCrossref
24.
Blomquist  PH Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis).  Trans Am Ophthalmol Soc 2006;104322- 345PubMedGoogle Scholar
25.
Freidlin  JAcharya  NLietman  TMCevallos  VWhitcher  JPMargolis  TP Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus.  Am J Ophthalmol 2007;144 (2) 313- 315PubMedGoogle ScholarCrossref
26.
Asbell  PAColby  KADeng  S  et al.  Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.  Am J Ophthalmol 2008;145 (6) 951- 958PubMedGoogle ScholarCrossref
27.
Chen  APrajna  LSrinivasan  M  et al.  Does in vitro susceptibility predict clinical outcome in bacterial keratitis?  Am J Ophthalmol 2008;145 (3) 409- 412PubMedGoogle ScholarCrossref
28.
Wilhelmus  KRAbshire  RLSchlech  BA Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis.  Arch Ophthalmol 2003;121 (9) 1229- 1233PubMedGoogle ScholarCrossref
29.
Allen  GPDeshpande  LM Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus (MRSA).  Int J Antimicrob Agents 2010;35 (1) 45- 49PubMedGoogle ScholarCrossref
Clinical Sciences
April 11, 2011

Topical Fluoroquinolone Use as a Risk Factor for In Vitro Fluoroquinolone Resistance in Ocular Cultures

Author Affiliations

Author Affiliations: Francis I. Proctor Foundation for Research in Ophthalmology (Drs Fintelmann, Hoskins, Lietman, Keenan, Gaynor, Cevallos, and Acharya), Departments of Ophthalmology (Drs Fintelmann, Hoskins, Lietman, Keenan, Gaynor, and Acharya) and Epidemiology & Biostatistics (Dr Lietman), and Institute for Global Health (Dr Lietman), University of California, San Francisco.

Arch Ophthalmol. 2011;129(4):399-402. doi:10.1001/archophthalmol.2011.45
Abstract

Objective  To determine whether recent use of topical fluoroquinolones is a risk factor for in vitro fluoroquinolone resistance in Staphylococcus aureus ocular isolates.

Methods  Disk diffusion susceptibility testing for ciprofloxacin, moxifloxacin, and gatifloxacin was performed for all ocular isolates of S aureus at the Francis I. Proctor Foundation microbiology laboratory from January 1, 2005, to December 31, 2008. The medical records of patients with positive S aureus cultures were reviewed to determine topical or systemic fluoroquinolone use within the 3 months prior to culture. The Fisher exact test was used to compare the proportion of patients who used topical fluoroquinolones in the past 3 months among fluoroquinolone-sensitive and -resistant cases. Logistic regression was used to determine risk factors for fluoroquinolone resistance.

Results  Of 200 S aureus cultures, 41 were resistant to ciprofloxacin, moxifloxacin, and gatifloxacin (20.5%). Fluoroquinolone-resistant S aureus isolates were from older patients (mean [SD] age, 65.5 [25.0] years) compared with fluoroquinolone-susceptible isolates (mean [SD] patient age, 52.1 [22.1] years) (P = .003). Use of fluoroquinolones within the 3 months before testing was more frequent in resistant isolates (29%) than in susceptible isolates (11%) (P = .005), as was recent hospitalization (22% of resistant isolates, 0% of susceptible isolates) (P < .001). In the multivariate regression analysis, topical fluoroquinolone use within 3 months was a significant predictor of fluoroquinolone resistance (P = .046), along with age, systemic immunosuppression, and topical fluoroquinolone use between 3 and 6 months before testing.

Conclusion  Recent topical fluoroquinolone use is significantly associated with fluoroquinolone resistance in S aureus isolates from ocular cultures.

×